Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Takatsugu, Matsumoto"'
Autor:
Takatsugu Matsumoto, Takayuki Shimizu, Shun Sato, Genki Tanaka, Takamune Yamaguchi, Kyung-Hwa Park, Yuhki Sakuraoka, Takayuki Shiraki, Shozo Mori, Yukihiro Iso, Takehiko Nemoto, Keiichi Kubota, Yumi Nozawa, Kazuyuki Ishida, Taku Aoki
Publikováno v:
Surgical Case Reports, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Background Microhepatocellular carcinoma with a gross bile duct tumor thrombus is extremely rare, making the correct preoperative diagnosis difficult. Case presentation A 78-year-old man was referred to our department for close examination o
Externí odkaz:
https://doaj.org/article/989043c0c86140b198044a8a44b77df1
Autor:
Yuhki Sakuraoka, Keiichi Kubota, Genki Tanaka, Takayuki Shimizu, Kazuma Tago, Kyung Hwa Park, Takatsugu Matsumoto, Takayuki Shiraki, Shozo Mori, Yukihiro Iso, Taku Aoki
Publikováno v:
World Journal of Surgical Oncology, Vol 18, Iss 1, Pp 1-9 (2020)
Abstract Background The tumor location is the most simple clinical factor and important in liver surgery to make surgical procedure. However, no previous study has investigated the prognostic differences and clinical features of hepatocellular carcin
Externí odkaz:
https://doaj.org/article/eeaf2385d4a94c79aa633c426fde0970
Autor:
Takayuki Shimizu, Keiichi Kubota, Takashi Suzuki, Takatsugu Matsumoto, Takayuki Shiraki, Yuhki Sakuraoka, Shozo Mori, Yukihiro Iso, Masato Kato, Mitsuru Ishizuka, Taku Aoki
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-5 (2019)
Abstract Background Although an inferior vena cava (IVC) filter is used for preventing pulmonary thromboembolism (PTE) in patients with deep vein thrombosis, IVC filter penetration in the duodenum is a rare complication. Case presentation A 35-year-o
Externí odkaz:
https://doaj.org/article/39df50d47d6041f68c1420ab1b34226a
Autor:
SHOTARO MIYASHITA, TAKAYUKI SHIMIZU, MITSURU ISHIZUKA, MAIKO NIKI, YUSUKE NISHI, NORISUKE SHIBUYA, HIROYUKI HACHIYA, TAKATSUGU MATSUMOTO, YUHKI SAKURAOKA, TAKAYUKI SHIRAKI, SHOZO MORI, YUKIHIRO ISO, ATSUSHI IRISAWA, TAKU AOKI
Publikováno v:
Anticancer Research. 43:2219-2225
Autor:
Shotaro MIYASHITA, Takayuki SHIMIZU, Maiko NIKI, Kotaro SUDA, Kyung Hwa PARK, Takatsugu MATSUMOTO, Takayuki SHIRAKI, Yuhki SAKURAOKA, Shozo MORI, Yukihiro ISO, Mitsuru ISHIZUKA, Taku AOKI, Junji KITA, Keiichi KUBOTA
Publikováno v:
Suizo. 37:47-54
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 83:866-870
Autor:
Shozo Mori, Takayuki Shimizu, Mitsuru Ishizuka, Shun Sato, Yukihiro Iso, Takayuki Shiraki, Yuhki Sakuraoka, Takatsugu Matsumoto, Keiichi Kubota, Taku Aoki
Publikováno v:
Anticancer Research. 41:5171-5177
BACKGROUND/AIM Computed tomography and positron emission tomography cannot detect all minute distant metastases and fully evaluate extensive vascular invasion in patients with pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to inve
Autor:
Mitsuru Ishizuka, Takayuki Shimizu, Taku Aoki, Kazuma Tago, Hiroyuki Hachiya, Kazutoshi Takagi, Keiichi Kubota, Norisuke Shibuya, Takatsugu Matsumoto
Publikováno v:
The American Surgeon. 88:2831-2841
Objective To compare the postoperative complications of intracorporeal anastomosis (ICA) and extracorporeal anastomosis (ECA) in patients undergoing laparoscopic right colectomy (LRC). Background Although several studies have compared postoperative c
Autor:
Yuhki Sakuraoka, Yukihiro Iso, Keiichi Kubota, Takamune Yamaguchi, Shozo Mori, Takayuki Shimizu, Kyung Hwa Park, Takatsugu Matsumoto, Taku Aoki, Takayuki Shiraki
Publikováno v:
Pancreas. 50:744-750
Although neoadjuvant chemotherapy (NAC)-gemcitabine plus S-1 (GS) has been reported to have a survival benefit in patients with resectable pancreatic ductal adenocarcinoma (PDAC), optimal candidates for NAC-GS have not been clearly identified.A total
Autor:
Yuhki Sakuraoka, Shozo Mori, Takayuki Shiraki, Yukihiro Iso, Takatsugu Matsumoto, Keiichi Kubota, Takamune Yamaguchi, Takayuki Shimizu, Kyung Hwa Park, Taku Aoki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:109-120
Recently, the number of patients with pancreatic ductal adenocarcinoma (PDAC) who have received both neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) has been increasing. However, whether adverse events (AEs) during AC influence the prog